Preclinical evaluation of an anti-HCV miRNA cluster for treatment of HCV infection

Molecular Therapy

Volumn 21, Issue 3, 2013, Pages 588-601

  Yang, Xiao ^a   Marcucci, Katherine ^a   Anguela, Xavier ^a   Couto, Linda B ^a,b  

^a CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^b STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; ENHANCED GREEN FLUORESCENT PROTEIN; MICRORNA CORE; MICRORNA NS5B; MICRORNA UNTRANSLATED REGION 1; MICRORNA UNTRANSLATED REGION 2; MICRORNA UNTRANSLATED REGION 3; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL COUNT; CONTROLLED STUDY; DRUG SCREENING; FEMALE; GENE CLUSTER; GENE EXPRESSION; GENE SILENCING; GENOTYPE; HEPATITIS C; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; REPLICON; RNA SEQUENCE; VIRAL CLEARANCE; VIRAL GENE DELIVERY SYSTEM; VIRUS ASSEMBLY; VIRUS GENOME; VIRUS INHIBITION; VIRUS TRANSMISSION;

ADENO-ASSOCIATED VIRUS; HEPATITIS C VIRUS; MUS;

EID: 84875209207     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.247     Document Type: Article

References (50)

1. Wasley, A and Alter, MJ (2000). Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 20: 1-16.
2. De Francesco, R and Migliaccio, G (2005). Challenges and successes in developing new therapies for hepatitis C. Nature 436: 953-960.
3. Nunnari, G and Schnell, MJ (2011). MicroRNA-122: a therapeutic target for hepatitis C virus (HCV) infection. Front Biosci (Schol Ed) 3: 1032-1037.
4. Bourlière, M, Khaloun, A, Wartelle-Bladou, C, Oules, V, Portal, I, Benali, S et al. (2011). Chronic hepatitis C: treatments of the future. Clin Res Hepatol Gastroenterol 35 Suppl 2: S84-S95.
5. Rong, L, Dahari, H, Ribeiro, RM and Perelson, AS (2010). Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2: 30ra32.
6. Yang, X, Haurigot, V, Zhou, S, Luo, G and Couto, LB (2010). Inhibition of hepatitis C virus replication using adeno-associated virus vector delivery of an exogenous antihepatitis C virus microRNA cluster. Hepatology 52: 1877-1887.
7. Khvorova, A, Reynolds, A and Jayasena, SD (2003). Functional siRNAs and miRNAs exhibit strand bias. Cell 115: 209-216.
8. Schwarz, DS, Hutvágner, G, Du, T, Xu, Z, Aronin, N and Zamore, PD (2003). Asymmetry in the assembly of the RNAi enzyme complex. Cell 115: 199-208.
9. Aagaard, LA, Zhang, J, von Eije, KJ, Li, H, Saetrom, P, Amarzguioui, M et al. (2008). Engineering and optimization of the miR-106b cluster for ectopic expression of multiplexed anti-HIV RNAs. Gene Ther 15: 1536-1549.
10. Liu, YP, Haasnoot, J, ter Brake, O, Berkhout, B and Konstantinova, P (2008). Inhibition of HIV-1 by multiple siRNAs expressed from a single microRNA polycistron. Nucleic Acids Res 36: 2811-2824.
11. Kato, T, Date, T, Murayama, A, Morikawa, K, Akazawa, D and Wakita, T (2006). Cell culture and infection system for hepatitis C virus. Nat Protoc 1: 2334-2339.
12. Jiang, J and Luo, G (2009). Apolipoprotein E but not B is required for the formation of infectious hepatitis C virus particles. J Virol 83: 12680-12691.
13. Chang, M, Williams, O, Mittler, J, Quintanilla, A, Carithers, RL Jr, Perkins, J et al. (2003). Dynamics of hepatitis C virus replication in human liver. Am J Pathol 163: 433-444.
14. Chaulk, SG, Thede, GL, Kent, OA, Xu, Z, Gesner, EM, Veldhoen, RA et al. (2011). Role of pri-miRNA tertiary structure in miR-17~92 miRNA biogenesis. RNA Biol 8: 1105-1114.
15. McBride, JL, Boudreau, RL, Harper, SQ, Staber, PD, Monteys, AM, Martins, I et al. (2008). Artificial miRNAs mitigate shRNA-mediated toxicity in the brain: implications for the therapeutic development of RNAi. Proc Natl Acad Sci USA 105: 5868-5873.
16. Jopling, CL, Yi, M, Lancaster, AM, Lemon, SM and Sarnow, P (2005). Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science 309: 1577-1581.
17. Niemeyer, GP, Herzog, RW, Mount, J, Arruda, VR, Tillson, DM, Hathcock, J et al. (2009). Long-term correction of inhibitor-prone hemophilia B dogs treated with liverdirected AAV2-mediated factor IX gene therapy. Blood 113: 797-806.
18. Nakai, H, Yant, SR, Storm, TA, Fuess, S, Meuse, L and Kay, MA (2001). Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol 75: 6969-6976.
19. Perni, RB, Almquist, SJ, Byrn, RA, Chandorkar, G, Chaturvedi, PR, Courtney, LF et al. (2006). Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrob Agents Chemother 50: 899-909.
20. McCarty, DM, Monahan, PE and Samulski, RJ (2001). Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther 8: 1248-1254.
21. Gao, GP, Alvira, MR, Wang, L, Calcedo, R, Johnston, J and Wilson, JM (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA 99: 11854-11859.
22. Liu, F, Song, Y and Liu, D (1999). Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 6: 1258-1266.
23. Meister, G and Tuschl, T (2004). Mechanisms of gene silencing by double-stranded RNA. Nature 431: 343-349.
24. Fabian, MR, Sonenberg, N and Filipowicz, W (2010). Regulation of mRNA translation and stability by microRNAs. Annu Rev Biochem 79: 351-379.
25. Robbins, M, Judge, A, Ambegia, E, Choi, C, Yaworski, E, Palmer, L et al. (2008). Misinterpreting the therapeutic effects of small interfering RNA caused by immune stimulation. Hum Gene Ther 19: 991-999.
26. Fagone, P, Wright, JF, Nathwani, AC, Nienhuis, AW, Davidoff, AM and Gray, JT (2012). Systemic errors in quantitative polymerase chain reaction titration of selfcomplementary adeno-associated viral vectors and improved alternative methods. Hum Gene Ther Methods 23: 1-7.
27. Wright, JF and Zelenaia, O (2011). Vector characterization methods for quality control testing of recombinant adeno-associated viruses. Methods Mol Biol 737: 247-278.
28. Sommer, JM, Smith, PH, Parthasarathy, S, Isaacs, J, Vijay, S, Kieran, J et al. (2003). Quantification of adeno-associated virus particles and empty capsids by optical density measurement. Mol Ther 7: 122-128.
29. Grimm, D, Streetz, KL, Jopling, CL, Storm, TA, Pandey, K, Davis, CR et al. (2006). Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441: 537-541.
30. Wilson, JA, Jayasena, S, Khvorova, A, Sabatinos, S, Rodrigue-Gervais, IG, Arya, S et al. (2003). RNA interference blocks gene expression and RNA synthesis from hepatitis C replicons propagated in human liver cells. Proc Natl Acad Sci USA 100: 2783-2788.
31. Berkhout, B (2004). RNA interference as an antiviral approach: targeting HIV-1. Curr Opin Mol Ther 6: 141-145.
32. Lee, NS and Rossi, JJ (2004). Control of HIV-1 replication by RNA interference. Virus Res 102: 53-58.
33. Leonard, JN and Schaffer, DV (2005). Computational design of antiviral RNA interference strategies that resist human immunodeficiency virus escape. J Virol 79: 1645-1654.
34. Guedj, J, Rong, L, Dahari, H and Perelson, AS (2010). A perspective on modelling hepatitis C virus infection. J Viral Hepat 17: 825-833.
35. Wang, L, Calcedo, R, Nichols, TC, Bellinger, DA, Dillow, A, Verma, IM et al. (2005). Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directed gene therapy. Blood 105: 3079-3086.
36. Gao, G, Lu, Y, Calcedo, R, Grant, RL, Bell, P, Wang, L et al. (2006). Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol Ther 13: 77-87.
37. Nathwani, AC, Tuddenham, EG, Rangarajan, S, Rosales, C, McIntosh, J, Linch, DC et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365: 2357-2365.
38. Stiffler, JD, Nguyen, M, Sohn, JA, Liu, C, Kaplan, D and Seeger, C (2009). Focal distribution of hepatitis C virus RNA in infected livers. PLoS ONE 4: e6661.
39. Schorey, JS and Bhatnagar, S (2008). Exosome function: from tumor immunology to pathogen biology. Traffic 9: 871-881.
40. Conde-Vancells, J, Rodriguez-Suarez, E, Embade, N, Gil, D, Matthiesen, R, Valle, M et al. (2008). Characterization and comprehensive proteome profiling of exosomes secreted by hepatocytes. J Proteome Res 7: 5157-5166.
41. Wang, Z, Ma, HI, Li, J, Sun, L, Zhang, J and Xiao, X (2003). Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther 10: 2105-2111.
42. Nathwani, AC, Gray, JT, Ng, CY, Zhou, J, Spence, Y, Waddington, SN et al. (2006). Self-complementary adeno-associated virus vectors containing a novel liver-specific human factor IX expression cassette enable highly efficient transduction of murine and nonhuman primate liver. Blood 107: 2653-2661.
43. McCarty, DM, Fu, H, Monahan, PE, Toulson, CE, Naik, P and Samulski, RJ (2003). Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther 10: 2112-2118.
44. Allay, JA, Sleep, S, Long, S, Tillman, DM, Clark, R, Carney, G et al. (2011). Good manufacturing practice production of self-complementary serotype 8 adenoassociated viral vector for a hemophilia B clinical trial. Hum Gene Ther 22: 595-604.
45. Mingozzi, F and High, KA (2011). Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 12: 341-355.
46. McBride, JL, Pitzer, MR, Boudreau, RL, Dufour, B, Hobbs, T, Ojeda, SR et al. (2011). Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington's disease. Mol Ther 19: 2152-2162.
47. Simonelli, F, Maguire, AM, Testa, F, Pierce, EA, Mingozzi, F, Bennicelli, JL et al. (2010). Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther 18: 643-650.
48. Martino, AT, Suzuki, M, Markusic, DM, Zolotukhin, I, Ryals, RC, Moghimi, B et al. (2011). The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood 117: 6459-6468.
49. Grimm, D, Zhou, S, Nakai, H, Thomas, CE, Storm, TA, Fuess, S et al. (2003). Preclinical in vivo evaluation of pseudotyped adeno-associated virus vectors for liver gene therapy. Blood 102: 2412-2419.
50. Takeuchi, T, Katsume, A, Tanaka, T, Abe, A, Inoue, K, Tsukiyama-Kohara, K et al. (1999). Real-time detection system for quantification of hepatitis C virus genome. Gastroenterology 116: 636-642.